Business Standard

After the anti-diabetic market, India's cardiac market in for a shake-up

Sun Pharma has the largest share in the Indian cardiac market, followed by Torrent Pharma, Lupin and USV

pharma, medicine, drugs
Premium

Sohini Das Mumbai
After the anti-diabetic market, India's cardiology market is now set for a churn as Swiss drugmaker Novartis’ blockbuster drug for heart failure patients Vymada or Entresto is set to go off patent in January.

Trade sources say that this is one of the fastest growing drugs in the Rs 23,000 crore cardiac market in the country.

Entresto or Vymada as it is sold in India is a combination of Sacubitril and Valsartan.

According to data from market research firm AWACS, the cardiac market in India is dominated by antihypertensives which contribute nearly 53 per cent of the market, followed by

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 03 2022 | 2:02 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com